Following this, three other clinical trials that are either completed or ongoing have focused on type 1 diabetes, where they tested proinsulin-loaded VitD3-tolDCs, monocyte-derived DCs treated with antisense oligonucleotides targeting CD80, CD86, CD40 and autologous dendritic cell therapy (see Table 1). The gene discussed is INS; the disease is type 1 diabetes mellitus.